Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02339974 · ClinicalTrials.gov registry record · Phase 3
Heterotopic Implantation Of the Edwards-Sapien Transcatheter Aortic Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation (HOVER)
A Phase 3 study, sponsored by Henry Ford Health System.
- Completed
- Registry status
- Phase 3
- Development phase
- 15
- Enrollment target
NCT02339974 is a Phase 3 study that has completed, run by Henry Ford Health System. The registered enrollment target is 15 participants.
The verdict
NCT02339974, a Phase 3 study, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 15 participants
- Enrollment target
Study Summary
The goal of this study is to determine the short term safety (\<30 days) and efficacy (6 months) of the heterotopic implantation of the Edwards-Sapien XT valve in the inferior vena cava for the treatment of severe tricuspid regurgitation in patients who are inoperable or at a very high surgical risk for tricuspid valve replacement.
Interventions
- DEVICE Heterotopic Implantation Of the Edwards-Sapien XT Transcatheter Valve in the Inferior VEna Cava
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-01 |
| Est. Completion | 2025-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02339974
The ClinicalTrials.gov registry entry for NCT02339974 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Heterotopic Implantation Of the Edwards-Sapien XT Transcatheter Valve in the Inferior VEna Cava is the first listed.
NCT02339974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02339974 about?
NCT02339974 is a clinical study titled "Heterotopic Implantation Of the Edwards-Sapien Transcatheter Aortic Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation (HOVER)". The goal of this study is to determine the short term safety (\<30 days) and efficacy (6 months) of the heterotopic implantation of the Edwards-Sapien XT valve in the inferior vena cava for the treatment of severe tricuspid regurgitation in patients who are inoperable or at a very high surgical risk...
What is the current status of trial NCT02339974?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 15 participants. The study started on 2015-01. Estimated completion is 2025-06.
What interventions are being tested in trial NCT02339974?
The interventions under investigation include: Heterotopic Implantation Of the Edwards-Sapien XT Transcatheter Valve in the Inferior VEna Cava (DEVICE).
Who is sponsoring clinical trial NCT02339974?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.